VivoSeq
Other

Arteriosclerosis Obliterans

4

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Arteriosclerosis Obliterans is an early-stage landscape with 4 programs across 5 companies. The most active players are Guangzhou Yipinhong Pharmaceutical CO.,LTD, Viatris Specialty LLC, Fresenius Kabi Oncology Ltd.. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Guangzhou Yipinhong Pharmaceutical CO.,LTD

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

ApprovedAbbVie logo

AbbVie

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Unknown status1 · 50%

Clinical Trials

Trial Activity

Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities.
Completed·—·Phase 4·NCT02107170·68 enrolled
A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
Unknown status·GGuangzhou Yipinhong Pharmaceutical CO.,LTD·Phase 2·NCT02877173·160 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)